See more : Ta Ann Holdings Berhad (5012.KL) Income Statement Analysis – Financial Results
Complete financial analysis of CervoMed Inc. (CRVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CervoMed Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Enauta Participações S.A. (ENAT3.SA) Income Statement Analysis – Financial Results
- Borussia Dortmund GmbH & Co. Kommanditgesellschaft auf Aktien (BVB.DE) Income Statement Analysis – Financial Results
- Bank of Qingdao Co., Ltd. (3866.HK) Income Statement Analysis – Financial Results
- Litium AB (publ) (LITI.ST) Income Statement Analysis – Financial Results
- LianDi Clean Technology, Inc. (LNDT) Income Statement Analysis – Financial Results
CervoMed Inc. (CRVO)
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 71.67K | 374.54K | 570.48K | 40.19K | 0.00 | 40.19K | 308.76K | 0.00 | 0.00 | 26.94M | 27.91M |
| Cost of Revenue | 8.44M | 1.34M | 93.42K | 103.17K | 97.92K | 110.37K | 67.98K | 25.34K | 8.27K | 566.26K | 675.76K | 235.80K | 2.31M | 210.39K | 47.20K | 24.68K | 134.15K | 0.00 | 0.00 | 26.89M | 23.60M |
| Gross Profit | -1.29M | -1.34M | -93.42K | -103.17K | -97.92K | -110.37K | -67.98K | -25.34K | -8.27K | -566.26K | -604.09K | 138.74K | -1.74M | -170.20K | -47.20K | 15.51K | 174.61K | 0.00 | 0.00 | 48.06K | 4.31M |
| Gross Profit Ratio | -18.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -842.91% | 37.04% | -304.68% | -423.51% | 0.00% | 38.59% | 56.55% | 0.00% | 0.00% | 0.18% | 15.45% |
| Research & Development | 8.44M | 1.34M | 8.50M | 9.43M | 6.62M | 5.75M | 5.09M | 6.25M | 3.88M | 2.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 465.91K | 300.00K |
| General & Administrative | 6.52M | 2.14M | 7.45M | 6.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.70M | 10.01M | 6.77M | 0.00 | 950.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.52M | 2.14M | 7.45M | 6.44M | 4.83M | 6.17M | 6.19M | 8.59M | 2.52M | 3.91M | 7.31M | 6.70M | 10.01M | 6.77M | 992.50K | 950.75K | 2.57M | 41.90K | 92.20K | 6.42M | 3.20M |
| Other Expenses | 0.00 | -2.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.23M | 4.69M | 699.67K | -1.91M | 1.29M | -490.01K | 0.00 | 0.00 | -6.84M | 813.03K |
| Operating Expenses | 14.96M | 3.48M | 15.94M | 15.87M | 11.45M | 11.92M | 11.28M | 14.85M | 6.40M | 6.77M | 7.31M | 11.93M | 14.69M | 7.47M | 2.90M | 2.24M | 3.06M | 41.90K | 92.20K | 48.06K | 4.31M |
| Cost & Expenses | 14.96M | 3.48M | 16.04M | 15.97M | 11.55M | 12.03M | 11.35M | 14.87M | 6.41M | 7.34M | 7.98M | 12.17M | 17.00M | 7.68M | 2.95M | 2.26M | 3.19M | 41.90K | 92.20K | 34.16M | 27.91M |
| Interest Income | 219.43K | 62.23K | 137.49K | 114.26K | 0.00 | 151.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 102.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 587.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.92M | 29.69K | 313.12K | 273.50K | 228.29K | 167.89K | 30.54K | 81.39K | 122.92K | 186.49K | 162.16K | 6.20K | 2.66K | 0.00 | 500.00K |
| Depreciation & Amortization | 5.64M | 3.48M | 93.42K | 103.17K | 97.92K | 110.37K | 67.98K | 25.34K | 8.27K | 566.26K | 675.76K | 164.04K | 119.81K | 49.67K | 47.20K | 55.85K | 58.03K | 0.00 | 0.00 | 386.99K | -200.00K |
| EBITDA | -2.17M | 0.00 | -24.45M | -15.76M | -11.37M | -18.70M | 566.01K | -18.35M | -6.40M | -16.33M | -1.55M | -6.65M | -22.49M | -8.28M | -3.23M | -1.15M | -2.45M | -41.90K | -92.20K | -6.84M | 813.03K |
| EBITDA Ratio | -30.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,168.22% | -1,774.94% | -3,941.53% | -20,599.03% | 0.00% | -2,865.27% | -792.06% | 0.00% | 0.00% | -25.38% | 2.91% |
| Operating Income | -7.81M | -3.48M | -16.04M | -15.97M | -11.55M | -12.03M | -11.35M | -14.87M | -6.41M | -7.34M | -7.91M | -11.79M | -16.43M | -7.64M | -2.95M | -2.22M | -2.88M | -41.90K | -92.20K | -7.22M | 613.03K |
| Operating Income Ratio | -109.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,039.83% | -3,148.34% | -2,879.94% | -19,002.60% | 0.00% | -5,529.81% | -934.14% | 0.00% | 0.00% | -26.82% | 2.20% |
| Total Other Income/Expenses | 5.64M | -2.33M | -8.50M | 114.25K | 85.30K | -6.78M | 8.93M | -3.53M | -313.12K | -9.83M | 5.45M | 4.94M | -6.21M | -772.65K | -452.64K | 2.22M | 218.50K | -6.20K | -2.66K | -836.31K | -613.03K |
| Income Before Tax | -2.17M | -5.80M | -24.54M | -15.86M | -11.47M | -18.81M | -2.42M | -18.40M | -6.72M | -17.17M | -2.46M | -6.85M | -22.64M | -8.41M | -3.40M | 0.00 | -2.67M | -48.10K | -94.86K | -8.06M | 0.00 |
| Income Before Tax Ratio | -30.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,429.68% | -1,828.85% | -3,967.89% | -20,925.14% | 0.00% | 0.00% | -863.38% | 0.00% | 0.00% | -29.92% | 0.00% |
| Income Tax Expense | 0.00 | -3.48M | -443.89K | -1.68M | 332.89K | -437.29K | -1.06M | -364.80K | 0.00 | -2.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.09M | 0.00 | 0.00 | 0.00 | 0.00 | -200.00K |
| Net Income | -2.17M | -5.80M | -24.10M | -14.19M | -11.80M | -18.37M | -1.36M | -18.04M | -6.72M | -14.35M | -2.46M | -6.87M | -22.64M | -8.41M | -3.40M | -2.09M | -2.67M | -48.10K | -94.86K | -8.06M | 200.00K |
| Net Income Ratio | -30.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,438.61% | -1,833.94% | -3,967.89% | -20,925.14% | 0.00% | -5,208.56% | -863.38% | 0.00% | 0.00% | -29.92% | 0.72% |
| EPS | -0.82 | -11.20 | -18.51 | -19.76 | -131.95 | -424.93 | -123.33 | -1.98K | -28.85K | -11.29K | -11.20K | -93.24K | -295.21K | -150.17K | -66.32K | -42.72K | -61.40K | -456.62K | -900.63K | 0.00 | 0.00 |
| EPS Diluted | -0.82 | -11.20 | -18.51 | -19.76 | -131.95 | -424.93 | -120.35 | -1.98K | -28.85K | -11.29K | -11.20K | -93.24K | -295.21K | -150.17K | -66.32K | -42.72K | -61.40K | -456.62K | -900.63K | 0.00 | 0.00 |
| Weighted Avg Shares Out | 2.66M | 518.14K | 1.30M | 717.76K | 89.42K | 43.23K | 11.06K | 9.10K | 232.88 | 1.27K | 235.25 | 79.00 | 78.00 | 56.00 | 51.28 | 49.00 | 43.42 | 0.11 | 0.11 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 2.66M | 518.14K | 1.30M | 717.76K | 89.42K | 43.23K | 11.34K | 9.10K | 232.88 | 1.27K | 235.25 | 79.00 | 78.00 | 56.00 | 51.28 | 49.00 | 43.42 | 0.11 | 0.11 | 0.00 | 0.00 |
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in October 2024; topline data expected in December 2024 –
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval
CervoMed to Participate in Upcoming Investor Conferences
BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company's Management will participate in the following investor conferences during the month of...
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC conference in January 2025 BOSTON, Oct. 29, 2024...
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
Dr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications” Dr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications”
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
CERVOMED INC (CRVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CervoMed to Participate in Upcoming Investor Conferences
BOSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company's management will participate in the following investor conferences during the month of...
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
BOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its recent feature in Fortune magazine.
Source: https://incomestatements.info
Category: Stock Reports